DJIA 17,976.31 263.65 1.49%
NASDAQ 4,947.44 56.22 1.15%
S&P 500 2,086.24 25.22 1.22%
market minute promo

Gilead Sciences (NASDAQ: GILD)



company name or ticker
Company Photos
(Click to zoom)

3 Triple-Digit Stocks With Upside Potential of At Least 40%

Just because these three companies trade north of $100 doesn't mean they're necessarily overvalued. Here are three triple-digit stocks with significant upside potential.

Gilead Sciences Inc. Faces An Uncertain Future After Patent Loss In India

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases

The Best Dividend-Paying Healthcare Stocks

These three healthcare stocks could offer the best blend of sales and dividend growth in the sector.

3 Best Dividend Stocks for 2015

These stocks offer attractive valuations and promising income streams. Check them out.

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

The Biggest Red Flag for Biotech Investors

Biotech stocks are chock-full of risk, but some dangers are more significant than others. Here is one key issue biotech investors should be tuned into going forward.

Could These Experimental Drugs Eclipse Harvoni's Historic Launch?

Harvoni set the standard for blockbuster drug launches -- but these three drugs just might have a shot at being even bigger.

Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog

Young Investors Should Hope for a Pullback Sooner Rather Than Later

See More Articles...